Chronic obstructive pulmonary disease is the fourth leading cause of death in the world and more than ten million people caught the disease in America. Due to the importance of chronic obstructive pulmonary disease in public health around the world, we aimed to investigate The effects of statins on pulmonary artery pressure in the patients with chronic obstructive pulmonary disease.
This triple blind, randomized control trials will perform on 21 COPD patients with atorvastatin treatment and 21 COPD patients without receiving any treatment who attended to Vali-Asr hospital, Birjand, East of Iran 2016. Inclusion criteria were as follow: no previous use of statins, Performing CBC, lipid profile, LTF, absence of liver disease, FEV1<80% and FEV1/FVC<70%. Also, patients excluded for the following reasons: discontinuation of statin therapy during the study, having advanced heart disease, the advent of statin therapy complications, long-term use of corticosteroid and death. Both groups will tested with echocardiography for presence of pulmonary hypertension by a cardiologist before taking atorvastatin and their pulmonary artery pressure will measured at baseline. In addition, Spirometry will perform in both groups. Case group receive 40mg statins per day for six month (24 weeks). At the end of this study, patients evaluate by spirometry and echocardiography.